Navigation Links
Genaera to Present at BIO CEO & Investor Conference
Date:2/5/2009

PLYMOUTH MEETING, Pa., Feb. 5 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) will present at the Eleventh Annual BIO CEO & Investor Conference, being held February 9-10, at the Waldorf-Astoria Hotel in New York. Jack Armstrong, President and Chief Executive Officer, will provide promising preliminary Phase 1b clinical data for MSI-1436, the first-in-class, highly selective inhibitor of PTP1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, on Tuesday, February 10, 2009 at 2:15 p.m. (ET).

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
2. Genaera to Present at Therapeutic Area Partnerships 2008
3. Genaera Receives Non-Compliance Notice From NASDAQ
4. Genaera Corporations 2008 Annual Stockholder Meeting Results
5. Xmark Comments on Genaera Cost-Saving Plan
6. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
9. Rigel to Present at BIO CEO & Investor Conference
10. Bionovo Announces Presentation at the National Cancer Institute
11. U.S. Preventive Medicine(R) Executives to Present at 2009 UBS Global Healthcare Services Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Marietta, GA (PRWEB) , ... April 25, 2017 ... ... implant and instrument solutions, announces the continuation of its strategic partnership with and ... surgeons in developing nations in the safe and effective management of complex spine ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... ... , ... The Santana Telehealth Project was honored with the 2017 ATA Humanitarian ... Association’s annual conference, on April 23 in Orlando, FL. , “I am proud that ... of the poor and underserved in other parts of the world,” said Jonathan Linkous, ...
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the ... Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced that it ... Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany ...
(Date:4/24/2017)... ... 24, 2017 , ... The bar for just about everything—apparel, eyewear, cars and ... air of pop and film stardom.(1) Not to be left out is that most ... now run the gamut from being encrusted with jewels and precious metals to, at ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: